Nov 20 (Reuters) – The US Food and Drug Administration declined to approve Capricor Therapeutics' experimental cell therapy for a fatal inherited disease that weakens muscle, the health regulator said
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Ernest Scheyder Nov 20 (Reuters) - US Commerce Secretary Howard Lutnick asked battery startup Pure…
Nov 20 (Reuters) - Hackers this week breached a system that the US Department of…
(Updates with second Riyadh warning) Nov 21 (Reuters) - Saudi Arabia's civil defence issued two…
VIDEO SHOWS: HIGHLIGHTS OF AL AHLI BEATING AL NASSR 3-1 IN THE SAUDI PRO LEAGUE…
SAUDI ARABIA'S CIVIL DEFENCE SAYS DANGER HAS PASSED IN RIYADH (The article has been published…
By Milana Vinn and Pritam Biswas Nov 20 (Reuters) - GTCR is exploring a potential…